Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

31.99 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2026 Add to My Watchlist

Price and Volume

Volume	41
Open	31.99
Bid (Size)	26.00 (1,500)
Ask (Size)	31.98 (100)
Prev. Close	31.99
Today's Range	31.99 - 31.99
52wk Range	12.91 - 42.13
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 24, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Performance

YTD	-19.1%	-19.1%
1 Month	-15.1%	-15.1%
3 Month	+7.9%	+7.9%
6 Month	+107.1%	+107.1%
1 Year	+56.4%	+56.4%

More News

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

January 16, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗

January 13, 2026

Via Stocktwits

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors ↗

January 05, 2026

Via Chartmill

Why Travere Therapeutics Stock Got Trounced on Tuesday ↗

January 13, 2026

Via The Motley Fool

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

Via MarketMinute

Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗

January 13, 2026

Via Stocktwits

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

January 13, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 13, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 13, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Tuesday. ↗

January 13, 2026

Via Chartmill

Travere Therapeutics Provides Corporate Update and 2026 Outlook

January 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗

December 24, 2025

Via The Motley Fool

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗

December 18, 2025

Via Chartmill

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗

November 27, 2025

Via Chartmill

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

Via The Motley Fool

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

Via The Motley Fool

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

November 06, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 04, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?

Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Travere Therapeutics, Inc. - Common Stock trade on?

Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?

The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market

What is the current price of Travere Therapeutics, Inc. - Common Stock?

The current price of Travere Therapeutics, Inc. - Common Stock is 31.99

When was Travere Therapeutics, Inc. - Common Stock last traded?

The last trade of Travere Therapeutics, Inc. - Common Stock was at 01/29/26 04:00 PM ET

What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?

The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.94B

How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?

Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.